文献速递血管炎

古塞奇尤单抗治疗新发或复发巨细胞动脉炎的2期随机安慰剂对照研究

A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis.
PubMed 文献 · Ann Rheum Dis · 2026-02-12

这项2期随机双盲安慰剂对照研究评估古塞奇尤单抗对比安慰剂治疗新发或复发巨细胞动脉炎(GCA),两组均接受背景糖皮质激素治疗。

要点

  • 第28周前发生GCA复发或因病情恶化停药的比例两组分别为31%和39%。
  • 截至第60周,两组不良事件发生率分别为97%和94%,常见为COVID-19感染和头痛。

核心结论

  • 研究未达到主要终点(第28周无GC缓解),结果不支持古塞奇尤单抗用于治疗GCA。

研究设计与样本

  • 随机、双盲、安慰剂对照的2期研究,纳入≥50岁新发或复发GCA患者,按2:1随机接受古塞奇尤单抗或安慰剂,两组均接受背景GC治疗并按方案在第26周前逐渐减量。

主要发现

  • 共35例随机至古塞奇尤单抗组、18例至安慰剂组;全部为白人,70%为女性,平均年龄71.5岁,60%为新发GCA、40%为复发GCA。
  • 第28周前发生GCA复发或因病情恶化停药的比例古塞奇尤单抗组为31%(11/35),安慰剂组为39%(7/18)。
  • 截至第60周不良事件发生率古塞奇尤单抗组为97%(34/35),安慰剂组为94%(17/18);除GCA恶化(49%和56%)外,常见不良事件为COVID-19感染(23%和28%)和头痛(17%和39%)。

临床怎么用

  • 现有证据不支持古塞奇尤单抗用于GCA治疗,临床决策应继续依据既有标准治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Guselkumab, a monoclonal antibody, selectively targets the p19 subunit of interleukin-23. This randomised, double-blind, placebo-controlled, phase 2 study evaluated guselkumab vs placebo for the treatment of giant cell arteritis (GCA). METHODS: Patients ≥50 years of age with new-onset or relapsing GCA were randomised 2:1 to guselkumab or placebo. Both arms received background glucocorticoid (GC) therapy, with a protocol-defined taper through week 26. The primary endpoint was the proportion of patients achieving GC-free remission at week 28. RESULTS: Thirty-five patients were randomised to receive guselkumab and 18 to receive placebo. All patients were White, 70% were female, and the mean age was 71.5 years; 60% had new-onset and 40% had relapsing GCA. At week 28, 40% (14/35) and 33% (6/18) of patients in the guselkumab and placebo groups, respectively, achieved GC-free remission (P = .64), whereas 31% (11/35) and 39% (7/18) had experienced a GCA flare or discontinued due to worsening GCA. Median time to first GCA flare through week 28 was not estimable (NE) in the guselkumab group (90% CI: 27.7-NE) and 29.7 weeks (90% CI: 20.1-NE) in the placebo group (P = .64). Through week 60, 97% (34/35) and 94% (17/18) of patients in the guselkumab and placebo groups, respectively, had adverse events (AEs); the most common AEs, aside from worsening of GCA (49% and 56%, respectively), were COVID-19 infection (23% and 28%) and headache (17% and 39%). CONCLUSIONS: The study's primary endpoint (GC-free remission) was not met; results do not support the use of guselkumab in the treatment of GCA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Makhzoum JP, Cid MC, Samson M, et al. A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis. Ann Rheum Dis. 2026. PMID: 41688258. doi:10.1016/j.ard.2026.01.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。